July 20, 2018

Allergan’s eye contender cannot knock Eylea off its perch

Allergan's wet AMD candidate abicipar has apparently succeeded in phase III – but a safety signal could make it hard to compete against Regeneron's Eylea.

January 26, 2018

Upcoming events – Gilead’s HIV approval and Apellis looks to geographic atrophy

December 01, 2017

Upcoming events – Twirla gets a second chance and Allergan targets new eye disease

November 27, 2017

Regeneron needs a new plan B for Eylea

September 15, 2017

Snippet roundup: Bad news for Sage and Santhera, good tidings for Glaxo and Bayer

August 18, 2017

Snippet roundup: Transparency for Straumann but a black box for Pfizer

February 09, 2017

More lost than gained in shifting R&D forecasts

January 06, 2017

Select small caps stand out amid wider 2016 stock market declines

January 06, 2017

Upcoming events – Regeneron's Eylea combo and Lundbeck takes on Alzheimer's, again